BFC Planning’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
Other funds holding ELVN
SL
BFC Planning's ELVN Position: Q3 2026 in Review
BFC Planning opened a new position in Enliven Therapeutics (ELVN) in Q3 2026: 10 shares worth $458. The stake represents ﹤0.01% of the portfolio and ranks #3297 among its holdings.
133 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.
- BFC Planning held 10 shares of Enliven Therapeutics worth $458 as of Q3 2026.
- Enliven Therapeutics was a new BFC Planning position in Q3 2026.
- Enliven Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3297 holding.
- 133 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.